Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $54.2 million.

  • Editas Medicine's Current Deferred Revenue fell 2131.58% to $54.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.2 million, marking a year-over-year decrease of 2131.58%. This contributed to the annual value of $60.4 million for FY2024, which is 1228.52% down from last year.
  • As of Q3 2025, Editas Medicine's Current Deferred Revenue stood at $54.2 million, which was down 2131.58% from $54.2 million recorded in Q2 2025.
  • Editas Medicine's 5-year Current Deferred Revenue high stood at $89.4 million for Q1 2021, and its period low was $54.2 million during Q2 2025.
  • Its 5-year average for Current Deferred Revenue is $69.2 million, with a median of $68.9 million in 2022.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first crashed by 5100.6% in 2021, then soared by 327.26% in 2023.
  • Editas Medicine's Current Deferred Revenue (Quarter) stood at $72.2 million in 2021, then decreased by 4.62% to $68.9 million in 2022, then changed by 0.0% to $68.9 million in 2023, then decreased by 12.29% to $60.4 million in 2024, then fell by 10.3% to $54.2 million in 2025.
  • Its Current Deferred Revenue stands at $54.2 million for Q3 2025, versus $54.2 million for Q2 2025 and $56.2 million for Q1 2025.